Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1487318
This article is part of the Research Topic Precision Oncology in Checkpoint Immunotherapy: Leveraging Predictive Biomarkers for Personalized Treatment View all 7 articles

Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy

Provisionally accepted
Nan Zhang Nan Zhang 1,2Shiyun Chen Shiyun Chen 3Yue Shi Yue Shi 3Zhikuan Wang Zhikuan Wang 3Ru Jia Ru Jia 3*Guang-hai Dai Guang-hai Dai 2,3*
  • 1 Medical School of Chinese People's Liberation Army, Beijing, China
  • 2 Department of Medical Oncology, The First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijng, China
  • 3 Department of Medical Oncology. The Fifth Medical Center of Chinese People’s Liberation Army(PLA) General Hospital, Beijing, China

The final, formatted version of the article will be published soon.

    Objective: The Charlson Comorbidity Index (CCI) is a widely utilized assessment tool for evaluating the mortality rate among patients with chronic diseases and tumors. Currently, there is a dearth of research investigating the correlation between CCI and survival rates in advanced pancreatic cancer patients received immunotherapy. Therefore, this study aims to elucidate the association between CCI and survival rates in real-world settings for pancreatic cancer patients received immunotherapy. Methods: A total of 104 patients with advanced pancreatic cancer who received immunotherapy at the General Hospital of the People's Liberation Army between September 2015 and September 2020 were included in this study. The patients were categorized into two groups based on their Charlson Comorbidity Index (CCI) scores: low CCI group (CCI <7) and high CCI group (CCI ≥7). The statistical analysis focused on examining the correlation between CCI score and survival outcome. Results: The high CCI group exhibited significantly lower overall survival (OS) and progression-free survival (PFS) compared to the low CCI group (p<0.05). The median OS for the high CCI and low CCI groups were 7.82 and 44.17 months, respectively, while the median PFS were 2.40 and 6.40 months, respectively. Multivariate analysis revealed that high CCI was independently risk factor for both OS (HR=2.801, 95%CI: 1.433-5.472, p=0.003) and PFS (HR=2.546, 95%CI: 1.389-4.668, p=0.003). Conclusion: The CCI score serves as a significant independent predictive indicator for advanced pancreatic cancer patients received immunotherapy.

    Keywords: Pancreatic Cancer, immune checkpoint inhibitors, Charlson syndrome index, Survival, immunotherapy combined therapy

    Received: 27 Aug 2024; Accepted: 03 Jan 2025.

    Copyright: © 2025 Zhang, Chen, Shi, Wang, Jia and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ru Jia, Department of Medical Oncology. The Fifth Medical Center of Chinese People’s Liberation Army(PLA) General Hospital, Beijing, China
    Guang-hai Dai, Department of Medical Oncology, The First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijng, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.